（卢馨，已届满离任） 本人作为广州迈普再生医学科技股份有限公司（以下简称"公司"、 "迈普医学"）独立董事，严格按照《公司法》《证券法》《上市公司独 立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关法律、法规以及《公司章程》的规定和要求，切实履行独立董 事忠实诚信和勤勉尽责的义务，始终站在独立公正的立场参与公司决 策，充分发挥独立董事的作用，积极促进公司健全内控制度及规范运 作，维护公司全体股东，尤其是中小股东的合法权益。 报告期内，因公司换届选举，本人自 2024 年 5 月 10 日起不再担 任公司第二届董事会独立董事、审计委员会召集人。现将本人在 2024 年度任职期间的工作情况汇报如下： 一、基本情况 迈普医学 2024 年度独立董事述职报告 广州迈普再生医学科技股份有限公司 2024 年度独立董事述职报告 二、独立董事年度履职情况 （一）出席董事会和股东大会会议情况 2024 年度，公司共召开 10 次董事会，3 次股东大会，在 2024 年 度任职期间，本人出席董事会、股东大会会议的情况如下： 迈普医学 202 ...

迈普医学（301033）公告，2024年营业收入为2.78亿元，同比增长20.61%。归属于上市公司股东的净利 润为7885.42万元，同比增长92.90%。公司拟向全体股东每10股派发现金红利6元(含税)，送红股0股(含 税)，以资本公积金向全体股东每10股转增0股。 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥73,703,893.55, representing a 28.84% increase compared to ¥57,206,084.70 in the same period last year[5] - Net profit attributable to shareholders reached ¥24,162,307.00, a significant increase of 61.68% from ¥14,944,754.94 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥22,924,937.92, marking an 89.89% increase from ¥12,072,555.57 in the previous year[5] - Basic earnings per share rose to ¥0.37, up 60.87% from ¥0.23 in the same period last year[5] - The diluted earnings per share increased to ¥0.36, reflecting a 56.52% rise from ¥0.23 year-on-year[5] - Total operating revenue for the first quarter reached ¥73,703,893.55, an increase of 29% compared to ¥57,206,084.70 in the previous year[22] - Total operating costs amounted to ¥48,479,325.85, up from ¥43,035,696.85, reflecting a rise of approximately 12%[22] - Net profit for the period was ¥24,162,307.00, representing a significant increase of 62% from ¥14,944,754.94 in the same quarter last year[23] - Basic earnings per share increased to ¥0.37 from ¥0.23, indicating a growth of 61% year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was ¥29,204,747.03, an 83.88% increase compared to ¥15,882,465.09 in the previous year[5] - The company reported a decrease in cash and cash equivalents to ¥38,367,077.66 from ¥57,454,182.63, indicating a decline of approximately 33.5%[16] - The net cash flow from operating activities increased to ¥29,204,747.03, up from ¥15,882,465.09 in the previous period, representing an increase of 83.5%[29] - Cash inflow from operating activities totaled ¥93,021,906.35, compared to ¥75,466,349.85 in the prior period, reflecting a growth of 23.3%[29] - Cash outflow from operating activities was ¥63,817,159.32, an increase from ¥59,583,884.76, marking a rise of 7.4%[29] - Total assets at the end of the reporting period were ¥815,969,916.38, a 2.09% increase from ¥799,230,324.84 at the end of the previous year[5] - The total assets of the company reached ¥815,969,916.38, compared to ¥799,230,324.84 in the previous period, marking a growth of approximately 2%[20] - The cash and cash equivalents at the end of the period decreased to ¥24,294,568.50 from ¥49,380,615.16, a decline of 50.8%[29] Shareholder Information - The company reported a total of 6,036 common shareholders at the end of the reporting period[11] - The top shareholder, Yuan Yuyu, holds 16.52% of the shares, amounting to 10,987,847 shares, with 8,240,885 shares pledged[11] - The total number of shareholders holding more than 5% of shares and the top 10 shareholders' participation in margin trading is not applicable, indicating stability in shareholder structure[13] - The company has established a unified action agreement between major shareholders, ensuring coordinated decision-making until at least March 31, 2025[13] - The total shares held by major shareholders and their unified action partners amount to 4,547,596 shares, representing a significant portion of the company's equity[13] Investments and Expenses - Research and development expenses rose to ¥7,846,308.01, up 49% from ¥5,277,861.55, highlighting the company's commitment to innovation[23] - The company reported a significant increase in investment income, which rose to ¥1,188,297.56 from ¥850,057.30, an increase of about 40%[23] - Other comprehensive income after tax amounted to ¥51,005.19, contributing positively to the overall financial performance[23] - Cash inflow from investment activities reached ¥164,037,204.41, compared to ¥116,272,060.74, indicating an increase of 41.0%[29] - The net cash flow from investment activities was -¥57,786,572.81, a decline from ¥16,818,004.39 in the previous period[29] - Cash outflow for investment activities was ¥221,823,777.22, significantly higher than ¥99,454,056.35, showing an increase of 123.5%[29] Liabilities and Equity - Total liabilities decreased to ¥88,015,519.85 from ¥99,565,631.88, a reduction of about 12%[20] - The company's total equity increased to ¥727,954,396.53, up from ¥699,664,692.96, reflecting a growth of approximately 4%[20] - Shareholders' equity attributable to the company reached ¥727,954,396.53, up 4.04% from ¥699,664,692.96 at the end of the previous year[5]

Financial Performance - The company reported a total revenue of 500 million RMB for the fiscal year 2024, representing a 15% increase compared to 2023 [12]. - The company's operating revenue for 2024 reached ¥278,442,127.39, representing a 20.61% increase compared to ¥230,869,676.55 in 2023 [17]. - Net profit attributable to shareholders for 2024 was ¥78,854,230.23, a significant increase of 92.90% from ¥40,877,390.16 in 2023 [17]. - The net profit after deducting non-recurring gains and losses was ¥68,113,273.78 for 2024, up 82.94% from ¥37,233,014.67 in 2023 [17]. - The basic earnings per share for 2024 was ¥1.20, a 93.55% increase from ¥0.62 in 2023 [17]. - The total assets at the end of 2024 amounted to ¥799,230,324.84, reflecting a 1.56% increase from ¥786,969,032.68 at the end of 2023 [17]. - The net assets attributable to shareholders increased by 10.03% to ¥699,664,692.96 at the end of 2024, compared to ¥635,858,213.41 at the end of 2023 [17]. - The company's revenue for the reporting period reached ¥278,442,127.39, representing a year-on-year increase of 20.61% compared to ¥230,869,676.55 in the previous year [64]. - The company aims to achieve a net profit of 89.71 million yuan in 2024, reflecting a year-on-year growth of 98.57% [44]. Market Position and Strategy - The company has achieved a market share of 25% in the domestic neurosurgery device market, up from 20% in the previous year [12]. - The company is focusing on expanding its product line in the neurosurgery sector, with new product launches expected in Q3 2025 [12]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings [12]. - The company plans to expand its market share and brand influence in both domestic and international markets, focusing on clinical needs and innovative solutions [55]. - The company has established partnerships with nearly 1,000 distributors, with products available in approximately 2,000 hospitals domestically and over 100 countries globally [45]. - The company is actively exploring overseas market conditions and the specific products being sold in those regions [110]. - The company aims to become a global leader in high-performance medical device services, focusing on expanding its product technology application platform [97]. - The company aims to become a leading provider of high-performance implantable medical devices in the neurosurgery field, leveraging a rich product portfolio and strict quality management [98]. Research and Development - The company has invested 20 million RMB in R&D for new biomaterials and medical devices, aiming to enhance its competitive edge in the market [12]. - The company has developed advanced manufacturing technology platforms to enhance its product offerings in neurosurgery, including digital design and precision processing [36]. - The company is in the clinical trial phase for a new hard meninges medical glue, aiming to expand its product usage scope [75]. - The company plans to launch a new absorbable hemostatic fluid gel, currently in the product finalization stage [76]. - The company has 10 Class III medical device registration certificates and holds 258 domestic patents, including 171 invention patents [59]. - The company has established a complete industrialization system for technology R&D, registration, and production transformation, aiming to enhance its core competitiveness [108]. Governance and Management - The company will continue to enhance its governance structure and internal control systems to comply with the latest regulatory requirements from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [101]. - The company has a structured approach to governance with a clear delineation of roles among its board members and management team [138][145]. - The company has a strong management team with diverse backgrounds in medical technology and finance, enhancing its operational capabilities [139][140][141]. - The company is committed to maintaining high standards of governance with the election of qualified independent directors and supervisors [138][145]. - The company has established a value management system and disclosed its valuation enhancement plan [114]. - The company emphasizes social responsibility and maintains a balance of interests among shareholders, employees, and other stakeholders [126]. Employee and Talent Development - The total number of employees at the end of the reporting period is 337, with 330 in the parent company and 7 in major subsidiaries [173]. - The company aims to combine individual and team performance in its compensation system to attract and retain talent [175]. - The company is committed to enhancing its talent development system and will implement the "Climber Navigation Plan" by 2025 [176]. - The company has implemented a performance assessment system for incentive recipients, categorizing evaluations into five levels: "S", "A", "B", "C", and "D" [197]. - The company’s human resources department is responsible for collecting and verifying performance data for the incentive plan [192]. Financial Policies and Shareholder Relations - The company plans to distribute a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued [4]. - The company’s cash dividend policy is in compliance with its articles of association and shareholder resolutions, ensuring the protection of minority shareholders' rights [181]. - The total cash dividend, including other methods, reached RMB 51,203,471.60, representing 100% of the total distributable profit [182]. - The company distributed a cash dividend of RMB 4.00 per 10 shares (including tax) for the 2023 profit distribution plan, with a total cash dividend amounting to RMB 39,700,158.60 [180]. - The company ensures equal treatment of all shareholders during general meetings and facilitates their participation to exercise their rights [200]. Risks and Challenges - The company faces risks related to new product development and technological iteration, emphasizing the need to strengthen its R&D capabilities and maintain market competitiveness [104]. - The company is exposed to risks from policy changes in the high-value medical device industry, particularly regarding healthcare cost control measures [106]. - Increased competition in the neurosurgery high-value medical consumables market necessitates continuous improvement in product development, quality management, and marketing strategies [108]. - The company recognizes the challenges in expanding its market presence among hospitals, particularly due to the limited number of bidding companies for similar products [107].

共同投资的进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-010 广州迈普再生医学科技股份有限公司 关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 1、为了进一步推进公司产业发展、基于战略规划考虑需要，公 司作为有限合伙人以自有资金 2,000 万元出资与德摩咨询（深圳）有 限公司（以下简称"德摩咨询"）、广州康臣药业有限公司（以下简 称"康臣药业"）、丁骏、张适安共同设立广东东纳协同产业投资合 伙企业（有限合伙）（以下简称"东纳协同"）。具体内容详见公司 于 2025 年 2 月 26 日披露的《关于与专业投资机构共同投资的公告》 （公告编号：2025-005）。 2、为进一步优化投资结构，提升投资价值，公司增加 1,000 万 元自有资金投资东纳协同，同时重庆莱美药业股份有限公司（以下简 称"莱美药业"）以自有资金 4,000 万元增资东纳协同。2025 年 3 月 4 日，公司与德摩咨询、康臣药业、莱美药业、丁骏、张适安签署 了《广东东纳协同产业投资合伙企业（ ...

减持时间届满的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-009 广州迈普再生医学科技股份有限公司 关于公司持股 5%以上股东减持时间届满的公告 公司持股 5%以上的股东深圳市凯盈科技有限公司、唐莹女士保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日披露了《关于公司持股 5%以上股东减持股份的预 披露公告》（公告编号：2024-069），公司持股 5%以上股东深圳市 凯盈科技有限公司（以下简称"深圳凯盈"）、唐莹女士均计划通过 集中竞价方式分别减持公司股份不超过 197,000 股、657,100 股，即 分别不超过公司总股本的 0.2962%、0.9878%(分别不超过剔除公司回 购专用账户股份数量后总股本的 0.2977%，0.9931%)，减持期间为自 预披露公告披露之日起 15 个交易日后的 3 个月内。具体内容详见公 司披露在巨潮资讯网（http://www.cninfo.com.cn ...

共同投资的进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-008 广州迈普再生医学科技股份有限公司 关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 1、为了进一步推进公司产业发展、基于战略规划考虑需要，公 司作为有限合伙人以自有资金 2,000 万元出资与德摩咨询（深圳）有 限公司（以下简称"德摩咨询"）、广州康臣药业有限公司（以下简 称"康臣药业"）、丁骏、张适安共同设立广东东纳协同产业投资合 伙企业（有限合伙）（以下简称"东纳协同"）。具体内容详见公司 于 2025 年 2 月 26 日披露的《关于与专业投资机构共同投资的公告》 （公告编号：2025-005）。 2、为进一步优化投资结构，提升投资价值，公司增加 1,000 万 元自有资金投资东纳协同，同时重庆莱美药业股份有限公司（以下简 称"莱美药业"）以自有资金 4,000 万元增资东纳协同。2025 年 3 月 4 日，公司与德摩咨询、康臣药业、莱美药业、丁骏、张适安签署 了《广东东纳协同产业投资合伙企业（ ...

广州迈普再生医学科技股份有限公司 关于公司产品获得欧盟 MDR 认证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 公司产品获得欧盟 MDR 认证的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-007 广州迈普再生医学科技股份有限公司（以下简称"公司"）硬脑 膜医用胶产品近日获得按照欧盟医疗器械法规（Medical Device REGULATION (EU) 2017/745，简称"MDR"）认证的证书，现将有关 情况公告如下： 一、MDR 认证证书主要内容 1 、 证 书 名 称 ： EU Technical Documentation Assessment Certificate 2、认证产品：ImmisealTM Dural Sealant System 3、证书编号：MDR 775574 R000 4、制造商：Medprin Regenerative Medical Technologies Co.,Ltd. 5、证书生效日期：2025 年 03 月 20 日 6、证书失效时间：2030 年 03 月 19 日 二、对 ...

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company is positioned as a leader in the field of regenerative medicine, particularly in neurosurgery, with a diverse range of products driving significant revenue growth [19][25]. - The implementation of centralized procurement across multiple regions is expected to be a key factor in the company's performance release [19][26]. - The company's financial performance is projected to improve significantly, with expected revenues of 286 million yuan in 2024, 367 million yuan in 2025, and 482 million yuan in 2026, alongside a substantial increase in net profit [2][26]. Summary by Sections Company Overview - The company, established in 2008, focuses on high-performance implantable medical devices for neurosurgery, offering solutions for cranial repair, cerebrospinal fluid sealing, and hemostatic products [19][21]. - It has registered 10 Class III medical devices and holds over 250 effective patents, with products used in over 1,700 hospitals across China [19][21]. Financial Performance - The company reported a revenue of 195 million yuan in 2022, with a year-on-year growth of 27%, and an expected revenue of 231 million yuan in 2023, reflecting an 18.2% increase [2][26]. - In the first three quarters of 2024, the company achieved a revenue of 190.94 million yuan, a year-on-year increase of 30.98%, and a net profit of 52.80 million yuan, up 107.68% [26]. Product Development and Market Position - The company has successfully entered multiple provincial centralized procurement programs, enhancing its market penetration and sales volume [19][24]. - The artificial dura mater products have seen significant sales growth, with a reported revenue of 122.05 million yuan in the first half of 2024, a 42.38% increase year-on-year [24]. - The company is also expanding its product offerings in hemostatic materials, with the absorbable regenerated cellulose product expected to break the long-standing import monopoly in the market [24][25]. Management and Corporate Structure - The management team has extensive experience in the medical device industry, contributing to the company's stable governance and strategic direction [39][43]. - The company has implemented stock incentive plans to align employee interests with long-term business goals, enhancing motivation and performance [46][47].

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company is positioned as a leader in the field of regenerative medicine, particularly in neurosurgery, with a diverse range of products driving significant revenue growth [19][25]. - The implementation of centralized procurement across multiple regions is expected to be a key factor in the company's performance release [19]. - The company has a stable management and ownership structure, with a stock incentive plan reflecting confidence in future business development [39][46]. Financial Forecast - The company is projected to achieve revenues of 286 million yuan in 2024, 367 million yuan in 2025, and 482 million yuan in 2026, with corresponding EPS of 1.09 yuan, 1.45 yuan, and 1.94 yuan respectively [2][9]. - The expected growth rates for revenue are 23.7% in 2024, 28.6% in 2025, and 31.3% in 2026 [2]. Business Overview - The company has a rich portfolio of neurosurgical products that meet various clinical needs, including artificial dura mater patches and hemostatic products [19][21]. - The company has successfully entered centralized procurement in several provinces, enhancing market penetration and sales volume [24][25]. - The company has established a strong international presence, with sales networks covering nearly 90 countries and regions, contributing to a 25.71% increase in overseas sales [25][26]. Product Development - The company has developed a comprehensive product matrix in neurosurgery, including artificial dura mater patches, craniofacial repair systems, and absorbable hemostatic products [19][21]. - The absorbable regenerated cellulose product is expected to break the long-standing import monopoly in the domestic market [24][25]. - The company has received multiple medical device registrations, enhancing its competitive edge in the market [19][20]. Management and Incentives - The management team possesses extensive experience in the medical device industry, contributing to the company's strategic direction and operational efficiency [39][43]. - The stock incentive plan aims to align employee interests with the company's long-term growth objectives, fostering motivation among key personnel [46][47].